ArticleFrontiers in neurology2025
Homocysteine, HHcy, H-type hypertension and dizziness: an NHANES analysis.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Homocysteine (Hcy) is associated with various diseases, but its specific relationship with different types of dizziness remains unclear. Objectives: This study utilizes NHANES cross-sectional data to investigate the associations between Hcy levels, H-type hypertension, and various symptomatic dizziness, aiming to provide new insights for clinical diagnosis and treatment. Materials and methods: This cross-sectional study analyzed 6,970 participants from NHANES (1999-2004) using weighted logistic regression, trend tests, restricted cubic spline analysis, and subgroup analysis. Results: Elevated Hcy levels and H-type hypertension showed significant positive associations with various symptomatic dizziness. HHcy showed the strongest association with fall risk (OR = 1.83, 95% CI: 1.24-2.77), while H-type hypertension was most strongly associated with any symptomatic dizziness (OR = 1.75, 95% CI: 1.34-2.28). No significant associations were found with positional dizziness. Trend analysis indicated a significant upward trend in the risk of any symptomatic dizziness, balance problems, and falling problems. RCS analysis demonstrated non-linear relationships between Hcy levels and various symptomatic dizziness, including any symptomatic dizziness, balance problems, and falling problems. Conclusions and significance: This study revealed that Hcy levels, HHcy, and H-type hypertension were significantly associated with various symptomatic dizziness. Recognizing and controlling HHcy and H-type hypertension are vital for dizziness management and diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.